B2i Digital

Asked why infected diabetic foot ulcers so often progress beyond the mild stage, Charles Zelen, DPM, FACFAS, founder and president of PERI, the clinical research organization conducting the company's Phase 2a trial of Nu-3, told a Lakewood-Amedex Biotherapeutics Inc. (@Nasdaq : $LABT) virtual roundtable that these patients are compromised hosts with multiple complex comorbidities and poor circulation. Lakewood-Amedex Biotherapeutics Inc. (@LakewoodAmedex) is a B2i Digital (@b2idigital) Featured Company. See the company's in-depth profile at: b2idigital.com/lakewood-amed… Zelen set out factors that, as he put it, have to be addressed simultaneously to heal these wounds: • Patients with poor circulation tend to have even greater problems dealing with infection and with bad wounds, he said • Neuropathy leaves patients unable to feel the infection going on, so it is often caught later, which he said makes it more difficult to treat • The wounds carry chronic inflammation and a complex wound environment, in his description, and antimicrobial resistance is also a big factor in this patient population Zelen closed by calling diabetic foot ulcers a serious and growing medical challenge, despite all the advances in wound care. "So this is a very big problem, very complicated problem, and one that we very much need to solve," Zelen noted, "or we're going to end up with a lot of lost extremities and a lot of deaths." Watch the full roundtable: youtu.be/EOIfDh8Vykk Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials, the Bisphosphocin® class, to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit lakewoodamedex.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. David Shapiro (@davidshapiroNYC), Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted LABT stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer.

Specialty cancer diagnostics company Precipio, Inc. (@PrecipioDx) (@Nasdaq : $PRPO) will be hosting its Q3-2026 shareholder update call on November 10, 2026, at 5:00 PM ET. The call will include remarks on the Company’s current core businesses, as well as a moderated live Q&A session at the end of the Company remarks. Precipio, Inc. is a B2i Digital (@b2idigital) Featured Company. See the company's in-depth profile at: b2idigital.com/precipio-inc-… This call will incorporate a dedicated moderated live Q&A session into its quarterly update, and listeners can join by phone, send questions in advance, or access the replay: • The conference call may be accessed by calling 646.307.1865, and all callers should ask for the Precipio Inc. conference call • Following Ilan Danieli’s remarks, the moderator will invite listeners to log into the Q&A system, where they will need to identify themselves and the organization they represent (or individual investor) • Listeners interested in submitting questions in advance can email them to [email protected] • A replay will be available approximately 24 hours after the call via the Investors page at precipiodx.com/investors/ Management looks forward to addressing investor questions and providing additional insight into the Company’s performance, strategy, and growth initiatives. “This quarter, our continued revenue growth was strengthened by Products Division revenues exceeding an important milestone, which we will share in our upcoming shareholder call. As this is also the last shareholder call for the year, we will be sharing some thoughts about where we envision 2027 and beyond taking us”, said Ilan Danieli, CEO. Read the full release: precipiodx.com/precipio-anno… Precipio is a healthcare biotechnology company focused on cancer diagnostics. Its mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services that deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in its laboratory where it designs, tests, validates, and uses these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis. More information is available at precipiodx.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer.

Safe Pro Group Inc. (@SafeProGroupCo) (@Nasdaq : $SPAI) has successfully completed all research milestones under the previously announced Phase I Small Business Innovation Research (SBIR) contract awarded by AFWERX in July. Subject to review and determination by AFWERX, Safe Pro intends to pursue additional SBIR-funded development contracts. Safe Pro Group Inc. is a B2i Digital (@b2idigital) Featured Company. See the company's in-depth profile at: b2idigital.com/safe-pro-grou… Focused on developing a new AI dataset using images of Foreign Object Debris/Damage (FOD) commonly encountered on both U.S. Air Force and civilian airfields, the SBIR work included: • Demonstration of SpotlightAI™ AI-powered computer vision technology for small object detection • Collection and analysis of high resolution imagery of FOD • Preparation of technical project reports Safe Pro says developing these AI datasets could significantly expand the applicability of its proprietary computer vision technology beyond battlefield and post-conflict zone land reclamation and rebuilding missions. “We wish to thank AFWERX for their collaboration on this project as we work to further demonstrate the significant value and impact that our patented AI-powered computer vision software technology can have in both defense and civilian applications,” said Dan Erdberg, Chairman and CEO of Safe Pro Group Inc. Read the full release: safeprogroup.com/safe-pro-su… Safe Pro Group Inc. (Nasdaq: SPAI) is a mission-driven technology company delivering AI-enabled security and defense solutions. Through cutting-edge platforms like SPAI Ground Truth, Safe Pro provides advanced situational awareness tools for defense, humanitarian, and homeland security applications globally. The Company is a leading provider of artificial intelligence (AI) solutions specializing in drone imagery processing and mapping, leveraging commercially available off-the-shelf drones with its proprietary machine learning and computer vision technology to enable rapid identification of explosive threats, providing a safer and more efficient alternative to traditional human-based analysis methods. Built on a cloud-based ecosystem and powered by Amazon Web Services (AWS), Safe Pro Group’s scalable platform targets multiple markets, including commercial, government, law enforcement, and humanitarian sectors where its Safe Pro AI software, Safe-Pro USA protective gear, and Airborne Response drone-based services can work in synergy to deliver safety and operational efficiency. For more information on Safe Pro Group Inc., please visit safeprogroup.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. David Shapiro (@davidshapiroNYC), Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted SPAI stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer.

ZenaTech, Inc. (@ZenatechInc) (@Nasdaq : $ZENA) today anticipates faster commercial survey delivery and increased capacity across its Drone as a Service (DaaS) land surveying operations through its recently unveiled proprietary AI software suite and drone surveying automation. The AI software suite is expected to begin formal testing across the DaaS network in 2027. ZenaTech, Inc. is a B2i Digital (@b2idigital) Featured Company. See the company's in-depth profile at: b2idigital.com/zenatech-1 On a representative 100-acre topographic survey, ZenaTech’s internal estimates compared field and office workflows: • Using conventional methods, a land surveyor typically covers about 3 acres a day, or approximately 267 hours of field work for the full site • Capturing the same site by drone requires approximately 65 hours • This comparison could indicate potential fieldwork time savings equivalent to more than 25 eight-hour workdays per 100-acre survey The Company’s AI addresses the next constraint: the office work after the drone lands. The Company’s proprietary AI software suite is designed to automate point cloud classification and feature extraction and has the potential to reduce post-processing workflows by as much as 80% according to internal estimates. Shaun Passley, Ph.D., CEO of ZenaTech, said: “Drones shorten the time in the field, and our AI is designed to shorten the time in the office.” Read the full release: zenatech.com/zenatech-antici… ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company that specializes in AI autonomy drone platforms to transform commercial, government, and defense sectors. Its subsidiaries include drone manufacturing through ZenaDrone, a global Drone as a Service (DaaS) business, and an enterprise SaaS division of software brands. The Company is executing an acquisition-led DaaS roll-up strategy to digitize and automate legacy service industries like land surveys and inspections, driving drone-based scalable, recurring revenue growth. With an operating footprint spanning North America, Europe, the Middle East, Asia, and Australia, ZenaTech is advancing AI drones for applications such as agriculture and logistics, as well as ISR, cargo, and counter-UAS for U.S. defense and NATO allies. The company is investing in next-generation technologies, including drone swarms, quantum computing, and advanced AI autonomy to capture long-term opportunities in key markets through its R&D initiatives. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. David Shapiro (@davidshapiroNYC), Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted ZENA stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer.

The 15th Annual ROTH Technology Conference takes place at the Hard Rock Hotel (@HardRockHotels) in New York City on Tuesday and Wednesday, November 17-18, 2026, hosted by ROTH Capital Partners (@ROTHCapital) with B2i Digital as Official Marketing Partner. The conference is a B2i Digital (@b2idigital ) Featured Conference. Event details and company profiles: b2idigital.com/roth-15th-ann… What to expect: Tuesday, November 17: themed fireside chats and a keynote speaker, 1:30 PM to 4:30 PM ET, followed by the ROTH Pre-Reception and the ROTH Cocktail Party Wednesday, November 18: 25-minute 1-on-1 and small group meetings between executive management and institutional investors, 9:00 AM to 5:00 PM ET Public and private companies across semiconductors, software, communications, AI and data center infrastructure, quantum computing, drones, aerospace and defense, digital assets and media Hard to believe it's been 5 years now working with ROTH. Their New York tech conference has all the key components: fireside chats, a keynote, and one-on-one investor meetings. 2 companies from our portfolio of Featured Companies are joining us, ZenaTech (@ZenatechInc) (NASDAQ: $ZENA) with its drones and Applied Energetics (@AELaserTech) (OTCQB: $AERG) with its counter-drone lasers. If you're an institutional investor, request your invite as soon as possible. Registration is subject to approval by ROTH: meetmax.com/sched/event_1393… Credit to the team at ROTH: Byron Roth, Aaron Gurewitz, Isabel Mattson-Pain, Nazan Akdeniz, Otilia "Charo" Montano, Amanda McAdams, Marc Lewis, Kamal Masud, Jesse Pichel, Robert Stephenson, Paul Zaffaroni, Matthew Day, Jonathan Alyn, Russ Nudelman, David Farina, Jacob Frank, Al Longfield, Michael Tait, Suji Desilva, Scott Searle, Bryan Baratian, Richard Baldry, Craig Irwin, Jeff Martin, Tom Hayes, Eric Handler, Taz Koujalgi, Gerry Sweeney and Sean McGowan. B2i Digital highlights the conference and the participating companies through the B2i Digital Media Network (b2idigital.com/media-network), 1,200+ outlets with a 330 million+ monthly audience, and its community of 1.7 million+ investors. The Capital Markets Matchmaker℠ takes every story From Marketing to Meetings℠. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is the Official Marketing Partner of the conference and is not an affiliate of ROTH. ZenaTech and Applied Energetics are B2i Digital Featured Companies and compensate B2i Digital for marketing services. David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted ZENA and AERG stock. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer.

Gold in three geological settings at the Parbec gold deposit was the subject Renforth Resources Inc. (@RenforthRes) (CSE: $RFR.CN | OTC: RFHRF) President and CEO Nicole Brewster took up when she presented at the Precious Metals & Critical Minerals Virtual Investor Conference on October 15, 2026. Parbec is located on the Cadillac Break just outside of Malartic, Quebec, where gold mineralization occurs within altered, fractured quartz-veined diorite intrusives and silicified feldspar porphyry bodies within and south of the Cadillac Break. Renforth Resources Inc. is a B2i Digital (@b2idigital) Featured Company. See the company's in-depth profile at: b2idigital.com/renforth-reso… Brewster set out the three settings in turn, moving from the main structure toward the north of the property: • The Cadillac Break itself, which she described as a crustal fault that starts in Kirkland Lake, Ontario, and extends past Val-d'Or in Quebec • A splay of the Cadillac Break into the sediments, the area the company set out to examine more closely with its stripping program • The island trench within the volcanics in the north, which she placed as the deepest pierce point on the property at 700 vertical metres, against a resource she said is only 300 metres deep On what the Cadillac Break has meant for mining across the region, Brewster noted: "Every kilometre is associated with a deposit or a mine, is the old rule of thumb. And we are in the shadow of headframes, the best place to find a new mine, as they used to say." Watch the full presentation: youtube.com/watch?v=v04estNh… Renforth Resources Inc. (CSE: RFR | OTC: RFHRF | FSE: 9RR) is a Canadian junior gold and critical minerals resource company focused on advancing the Parbec gold deposit in the prolific Abitibi region of Québec to the point where Renforth can monetize Parbec in order to develop Renforth’s Victoria nickel focussed bulk tonnage polymetallic deposit. Parbec is strategically located immediately adjacent to Agnico Eagle Mines Limited's (TSX: AEM | NYSE: AEM) Canadian Malartic complex, one of the largest open-pit gold mines in Canada. Renforth’s Victoria Ni/Cu/Co/Zn polymetallic deposit is also contiguous to Canadian Malartic, with a resource declared over only 12% of the ~20km length of the mineralized structure, forming part of a wholly owned district scale property with several mineralized occurrences. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer.

At the National Investment Banking Association (NIBA) (@NIBAnet) 153rd Investment Conference in Fort Lauderdale, Florida, on October 7, 2026, Robert Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals Corp. (@phio_pharma) (@Nasdaq : $PHIO), cited the company's 54 issued patents and described treating at the source as what sets PH-762 apart from everything else. PH-762 is the INTASYL® compound in Phio's lead clinical development program, and the completed Phase 1b study evaluated it in cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. Phio Pharmaceuticals Corp. is a B2i Digital (@b2idigital) Featured Company. See the company's in-depth profile at: b2idigital.com/phio-pharmace… PH-762 is an INTASYL compound delivered intratumorally, and the science behind it covers the INTASYL chemistry, how PH-762 acts on PD-1 and what it showed in non-clinical studies: • INTASYL compounds are based on short interfering RNA and have a single-stranded phosphorothioate region, a short duplex region and a variety of nuclease-stabilizing and lipophilic chemical modifications • PH-762 is designed to act locally to silence PD-1, the checkpoint receptor on T cells whose inhibitory signal suppresses T-cell activity when engaged • In Phio's non-clinical studies, direct-to-tumor administration of PH-762 resulted in activity against distant untreated tumors, indicative of a systemic anti-tumor response Describing what he sees as the difference between PH-762 and other treatments, Bitterman returned to where the drug acts, observing: "We have something that makes this drug very different than everything else. We treat it at its source." Watch the full presentation: youtu.be/9qRhYa1tOCw Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio’s INTASYL compounds are designed to enhance the body’s immune cells to more effectively kill cancer cells. Phio’s lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers. For additional information, visit the Company’s website, phiopharma.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.

Rocket Doctor AI Inc. (@rocketdoctor) (CSE: $AIDR.CN, OTC: AIRDF, Frankfurt: 939) Chief Executive Officer Dr. Essam Hamza told the National Investment Banking Association (NIBA) (@NIBAnet) 153rd Investment Conference in Fort Lauderdale, Florida, on October 7, 2026, that healthcare is moving away from fee-for-service toward value-based care, which rewards doctors and healthcare companies for keeping patients healthy. Rocket Doctor announced its first U.S. value-based primary care agreement on June 30, 2026, with a California independent physician association. Rocket Doctor AI Inc. is a B2i Digital (@b2idigital) Featured Company. See the company's in-depth profile at: b2idigital.com/rocket-doctor… In Dr. Hamza's account, the shift changes what doctors and healthcare companies are paid for, and when: • As Dr. Hamza described it, fee-for-service is a business where the doctor only sees a patient when the patient is sick • Under value-based care, he said, a healthcare company is paid for visits and also for keeping patients out of hospital and free of complications, with heart disease among his examples • He added that increasingly more payers are seeing the value in that model Regarding where healthcare payment is heading, Dr. Essam Hamza, Chief Executive Officer of Rocket Doctor AI Inc., stated: "And what's exciting is that healthcare is moving away from a fee-for-service business where we only see you when you're sick, which makes no sense to me, to actually rewarding doctors and healthcare companies, rewarding them for keeping you healthy and out of the office." Watch the full presentation: youtu.be/0o2GNoayczk Rocket Doctor AI Inc. delivers physician-guided, AI-powered solutions built to make high-quality healthcare accessible throughout the entire patient journey. A cornerstone of its proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians worldwide. Alongside the GLM is its digital health platform and marketplace which allows physicians to set up their own virtual practices and to date has helped more than 350 physicians support over 800,000 patient visits across U.S. and Canada. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer.

374Water Inc. (@374water) (@Nasdaq : $SCWO) today outlined how the EPA's PFAS drinking water regulations are expected to drive demand for the permanent destruction of spent granular activated carbon (GAC) and ion exchange (IX) media, and how it is positioning AirSCWO and its Waste Destruction Services to meet that demand. 374Water, Inc. is a B2i Digital (@b2idigital) Featured Company. See the company's in-depth profile at: b2idigital.com/374water-inc-… The company is positioned to serve the spent-media destruction market as it expands: • Final EPA nationwide monitoring data released in August 2026 show more than 10% of the approximately 10,000 public water systems with complete results above at least one PFAS maximum contaminant level • GAC and IX systems in service generate spent media on a recurring basis as beds reach breakthrough and are replaced, often annually • In an Army Corps of Engineers report authored by Arcadis, an AirSCWO system in Orlando achieved 99.9993% total PFAS destruction and removal efficiency on aqueous film-forming foam, measured across 42 PFAS species AirSCWO is designed to process solid wastes, including spent GAC and IX resin. Brad Meyers, COO of 374Water, stated: "Because AirSCWO can process solids, we can take the spent carbon and resin itself, not just liquid concentrates, and we are already building that model in Orlando." Read the full release: accessnewswire.com/newsroom/… 374Water Inc. (NASDAQ: SCWO) is a cleantech and environmental services company deploying supercritical water oxidation technology for the destruction of organic waste streams within the industrial, municipal, and federal markets. 374Water's AirSCWO technology is designed to efficiently destroy and mineralize a broad spectrum of nonhazardous and hazardous organic wastes, producing safe dischargeable water streams, safe mineral effluent, safe vent gas, and recoverable heat energy. 374Water's AirSCWO technology has the potential to assist its customers to meet discharge requirements, reduce or eliminate disposal costs, remove bottlenecks, and reduce litigation and other risks. 374Water continues to be a leader in innovative waste treatment solutions, dedicated to creating a greener future and eradicating harmful pollutants. Learn more by visiting 374water.com and follow us on LinkedIn. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. David Shapiro, (@davidshapiroNYC) Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted SCWO stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer.

Lithium iron phosphate battery cells made with phosphate from First Phosphate Corp. (@FirstPhosphate) (@Nasdaq : $PHOS) (CSE: PHOS) (OTCQX: FRSPF) (FSE: KD0) have been charged and discharged 2,000 times at full commercial scale, Chief Executive Officer John Passalacqua told the Precious Metals and Critical Minerals Virtual Investor Conference. He presented the cells as proof that North American critical minerals, including the company's phosphate and phosphoric acid, can go into making LFP batteries from North American critical minerals. First Phosphate Corp. is a New and Notable company in the B2i Digital (@b2idigital) network. To learn more, visit firstphosphate.com Passalacqua traced the path from Québec rock to a finished LFP battery cell and the supply chain associated with it: • He said the company worked with major partners to take igneous phosphate rock through concentrate, purified phosphoric acid, iron phosphate precursor and LFP cathode active material, and that Ultion, a partner in Nevada, made the cells • These are likely the first LFP battery cells produced using North American critical minerals in the anode and the cathode in the last 25 years, by his account • He said only 150 cells were made for the proof of concept LFP battery cells • The LFP battery supply chain was one of three, he said, that were threatened during recent trade disputes between China and the US, alongside rare earths and semiconductors On the testing behind those LFP battery cells made of North American critical minerals, "The batteries were cycled at full commercial scale. They were charged and discharged 2000 times," said Passalacqua. "And they work just like any other battery in the market, which means that all the critical minerals that went into them, and the process and all the partners, are validated." Watch the full presentation: youtube.com/watch?v=9m-d5k6q… First Phosphate Corp. (NASDAQ: PHOS) (CSE: PHOS) (OTCQX: FRSPF) (FSE: KD0) is a mineral exploration and development and clean technology company dedicated to building and reshoring a vertically integrated mine-to-market supply chain for the production of LFP batteries in North America. Target markets include energy storage, data centers, robotics, mobility, and national security. First Phosphate's flagship Bégin-Lamarche property, located in Saguenay-Lac-Saint-Jean, Québec, Canada, represents a rare North American high-purity igneous phosphate resource of high-purity phosphate characterized by very low levels of impurities. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

Hayasa Metals Inc. (TSXV: $HAY.V | OTCQB: HAYAF) has become a B2i Digital Featured Company, and B2i Digital (@b2idigital) will introduce the company to its network of retail and institutional market participants. Hayasa is exploring for copper and gold in Armenia, where mining accounts for 30% to 50% of the country's exports. As a new B2i Digital Featured Company, a full company profile is coming soon to b2idigital.com/featured-comp… Under a term sheet signed in September, a major mining company has funded copper exploration in southern Armenia with stream sediment and soil sampling almost complete, while drilling at Hayasa's own Urasar project awaits assays: • The two-year Strategic Exploration Alliance is funded solely by the partner and is aimed at finding a long-life copper porphyry, with Hayasa as manager and a definitive agreement expected before year end • At the 100%-owned Urasar copper-gold project, diamond drill hole UDD-021 returned 39 meters of 0.50% copper and 0.18 g/t gold from 11 meters in late 2025, and assays are pending from the first two holes drilled to depth in summer 2026 • Franco-Nevada and EMX Royalty paid US$1 million in January 2025 for a 1.25% royalty on future production from Urasar • Three new exploration licenses are in application, with approval expected in Q1 2027 "Hayasa has spent five years building a local team and a project portfolio in Armenia, and under the term sheet we signed in September, a major mining company has funded copper exploration in the south of the country. We have almost completed our planned work ahead of schedule," said Joel Sutherland, Chief Executive Officer of Hayasa Metals Inc. Learn more about Hayasa Metals: hayasametals.com Hayasa Metals Inc. is a copper and gold exploration company focused on advancing its highly prospective projects in Armenia. The Company is committed to responsible exploration and sustainable development practices while creating long-term value for shareholders. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer.